Hangalapura, Basav N <br/><br/>
Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.  [electronic resource] 

 -  Vaccine  Mar 2011 
 - 2313-21 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-2518 
<br/><br/><label>Standard No.: </label>10.1016/j.vaccine.2011.01.022  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenoviridae--genetics<br/>Animals<br/>Antigen-Presenting Cells--immunology<br/>CD8-Positive T-Lymphocytes--immunology<br/>Cancer Vaccines--administration & dosage<br/>Cross-Priming<br/>Dendritic Cells--immunology<br/>Injections, Intradermal<br/>Injections, Intravenous<br/>Lymph Nodes--immunology<br/>Melanoma, Experimental--immunology<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Knockout<br/>Myeloid Differentiation Factor 88--metabolism